Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Smad4 is involved in cancer progression and metastasis.
|
20797318 |
2010 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we examined Smad4 and Smad7 expression in gastric carcinomas to elucidate their role in tumor progression.
|
24659668 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, SMAD4 immunohistochemistry as a marker of SMAD4 gene status and the role of SMAD4 in the adenoma-carcinoma sequence in neoplastic progression in JPS are studied.
|
20682711 |
2010 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
KEY POINTS: A rare exon 18 epidermal growth factor receptor mutation with sensitivity to afatinib is reported.Small cell transformation was observed at tumor progression.Acquisition of a SMAD4 mutation was observed at tumor progression.
|
30413663 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
|
10766191 |
2000 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Smad4 is a critical factor in the TGF-β pathway and is involved in tumor progression and metastasis, but the role of Smad4 in colon cancer cells is unclear.
|
28445620 |
2017 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Inactivation of the DPC4 gene occurs late in the neoplastic progression of pancreatic carcinoma.
|
14607700 |
2002 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Deleted in pancreatic carcinoma locus 4 influences tumorigenesis and tumor progression by various mechanisms, including apoptosis.
|
18620728 |
2008 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Differences in allelic imbalance (AI) and mutations of the SMAD4/DPC4 gene between diploid and aneuploid populations were analyzed for 30 sporadic DNA multiploid colorectal carcinomas (used as a tumor progression model and defined as the coexistence of diploid and aneuploid cells within the same tumor).
|
16082587 |
2005 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TGF-beta is a potent inhibitor of the growth of epithelial cells; thus, it has been assumed that loss of Smad4 during tumor progression relieves this inhibition.
|
10944227 |
2000 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
High frequent G>T transversions in APC and KRAS2 (mutated in early tumour development) but not in P53 and SMAD4 (implicated in tumour progression) might indicate a predominant MUTYH effect in early carcinogenesis.
|
19527492 |
2009 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RNF11 acts directly on Smad4 to enhance Smad4 function, and plays a role in prolonged TGF-beta signalling and possibly in latent tumour progression.
|
19528490 |
2009 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
SMAD4 is a common signaling during tumor progression, and it can inhibit cell proliferation and promote cell motility in most epithelial cells.
|
30745456 |
2019 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
CTGF is induced by TGFbeta in diverse cell types, but TGFbeta receptor mediated signaling is impaired in pancreatic cancers and cell lines, usually due to DPC4/Smad4 mutations which arise during the later stages of intraepithelial neoplastic progression.
|
17786299 |
2007 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, an immunohistochemical analysis for abnormalities in the expression of five molecular parameters: MUC1, p16, p53, Smad4 and sonic hedgehog, which are associated with tumor progression, was performed.
|
24297432 |
2014 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Functional analysis through shRNA-mediated stable knockdown of SMAD4 in microglia revealed the downregulation of the expression of matrix metalloproteinase 9 (MMP9), which has been shown to be involved in tumor progression and cell migration.
|
29861845 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These observations indicate that Smad4/Pten-mutant mice mimic the tumor progression of human pancreatic cancers that are driven by activation of the AKT-mTOR pathway, and uncovered a synergistic action of Smad4 and Pten in repressing pancreatic tumorigenesis.
|
19901970 |
2010 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Chromosomal loss within the region of 18q and loss of SMAD4 expression have been reported to be frequent somatic events during colorectal cancer tumour progression; however, their associations with age at onset have not been widely studied.
|
19183329 |
2010 |